Free shipping on all orders over $ 500
Aunp-12 (NP-12) TFA is a peptide antagonist of the PD-1 signaling pathway, which has an equivalent antagonistic effect on PD-L1 and PD-L2 in terms of inhibiting lymphocyte proliferation and effector function. Aunp-12 TFA has immune-activating effect and good anti-tumor activity, which has the potential to better study immune-related adverse events (irAEs).
| Species | Mouse | Rat | Rabbit | Guinea pig | Hamster | Dog |
| Weight (kg) | 0.02 | 0.15 | 1.8 | 0.4 | 0.08 | 10 |
| Body Surface Area (m2) | 0.007 | 0.025 | 0.15 | 0.05 | 0.02 | 0.5 |
| Km factor | 3 | 6 | 12 | 8 | 5 | 20 |
| Animal A (mg/kg) = Animal B (mg/kg) multiplied by | Animal B Km |
| Animal A Km |
For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.
| Molecular Weight | 3375.57 |
| Formula | C5H17TFIN2O2S2Si |
| CAS Number | 1353563-85-5（free base) |
| Purity | >96% |
| Solubility | N/A |
| Storage | at -20°C |
| Related PD-1/PD-L1 Products |
|---|
| Evixapodlin
Evixapodlin (PD-1/ PD-L1-in 7) is an inhibitor of human PD-1/PD-L1 protein/protein interaction with an IC50 of 0.213 nM. Evixapodlin has anti-cancer and anti-virus properties. |
| INCB086550
INCB086550 selectively inhibited PD-L1 with IC50 of 3.1 nM, 4.9 nM and 1.9 nM for human, rhesus monkey and rat pD-L1, respectively. INCB086550 could not inhibit the binding of PD-L2 to PD-1 at 10 μM. INCB086550 significantly inhibits the PD-1/PD-L1 signaling axis by binding to PD-L1 protein, leading to PD-L1 dimerization and internalization, and has good tumor suppressive effect in a variety of mouse tumor models. |
| Spartalizumab
Spartalizumab (anti-PD-1) is a human-derived IgG4 antibody against PD-1 that inhibits the binding of PD-L1 and PD-L2 to PD-1. PDR001 binds to PD-1 with high affinity to inhibit its biological activity; MW: 145.8 KD. |
| BMS-1166
BMS-1166 is a potent PD-1/PD-L1 interaction inhibitor, which binds to human PD-L1 and blocks its interaction with PD-1. |
| BMS-1001
Bms-1001 Hydrochloride is orally active and is an inhibitor of the human PD-L1/PD-1 immune checkpoint. Bms-1001 Hydrochloride is characterized by low cytotoxicity.r. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2020 AbMole BioScience. All Rights Reserved.
